专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

61. 发明申请

US20140227339A1 REGENERATIVE TISSUE GRAFTS AND METHODS OF MAKING SAME 审中-公开
标题翻译：再生组织和其制备方法
公开(公告)号：US20140227339A1
公开(公告)日：2014-08-14
申请号：US14178932
申请日：2014-02-12
申请人： Wesley M. Jackson , Leon J. Nesti , Rocky S. Tuan
发明人： Wesley M. Jackson , Leon J. Nesti , Rocky S. Tuan
IPC分类号： A61K9/70 , A61K45/06 , A61K35/28
CPC分类号： A61K9/70 , A61F2/02 , A61F2/062 , A61F2210/0004 , A61F2250/0067 , A61K35/28 , A61K45/06 , A61K2035/124 , A61L27/18 , A61L27/34 , A61L27/3834 , A61L27/54 , A61L27/56 , A61L27/58 , A61L2400/12 , A61L2430/32 , C12N5/0663 , C12N5/0668 , C12N2500/40 , C12N2500/44 , C12N2501/01 , C12N2501/11 , C12N2501/115 , C12N2501/13 , C12N2501/235 , C12N2501/33 , C12N2501/385 , C12N2501/39 , C12N2533/40 , C08L67/04
摘要： A graft containing a scaffold that includes a matrix in which are positioned mesenchymal progenitor cells (MPCs) has the capacity to substantially improve wound healing, including wounds resulting from injury to nerve, bone and vascular tissue. MPCs can be harvested from debrided muscle tissue following orthopaedic trauma. The traumatized muscle-derived progenitor cells are a readily available autologous cell source that can be utilized to effect or improve wound healing in a variety of therapeutic settings and vehicles.
摘要翻译：包含其中位于间充质祖细胞（MPC）的基质的支架的移植物具有显着改善伤口愈合的能力，包括由神经，骨和血管组织损伤引起的伤口。在骨科创伤后，可以从清创肌肉组织收获MPC。受创伤的肌肉来源的祖细胞是易于获得的自体细胞源，其可用于在各种治疗设置和载体中实现或改善伤口愈合。

62. 发明申请

US20140178987A1 Stem cell culture medium and its applications as well as a stem cell culture method 有权
标题翻译：干细胞培养基及其应用以及干细胞培养方法
公开(公告)号：US20140178987A1
公开(公告)日：2014-06-26
申请号：US13885000
申请日：2013-01-31
申请人： Shanghai Tenth People's Hospital
发明人： Xiaoqing Liu , Ming Ying , Guangfeng Chen , Longpo Zheng
IPC分类号： C12N5/0775 , C12N5/0735
CPC分类号： C12N5/0667 , C12N5/0663 , C12N5/0665 , C12N2500/32 , C12N2500/33 , C12N2500/36 , C12N2500/38 , C12N2500/90 , C12N2501/105 , C12N2501/11 , C12N2501/113 , C12N2501/115 , C12N2501/125 , C12N2501/135 , C12N2501/165 , C12N2501/235 , C12N2501/39 , C12N2501/91
摘要： The present invention discloses a stem cell culture medium and its applications as well as a stem cell culture method. The said stem cell culture medium contains no serum. The said stem cell culture medium contains amino acids, vitamins, salts, lipids, cytokines and protein polypeptides. The said stem cell culture medium is suitable for rapid culture of stem cells derived from human and mammalian tissues, including but not limited to, adipose mesenchymal stem cells, bone marrow mesenchymal stem cells and umbilical cord blood stem cells. The said culture medium can increase the proliferation speed of the stem cells 3-5 times, without any affects on their differentiation potentials. Comparing the said stem cell culture medium to a routine culture medium, the said culture medium is not only able to proliferate stem cells derived from different sources more rapidly and achieve more proliferation generations, but also keep their differentiation potentials well.
摘要翻译：本发明公开了一种干细胞培养基及其应用以及干细胞培养方法。所述干细胞培养基不含血清。所述干细胞培养基含有氨基酸，维生素，盐，脂质，细胞因子和蛋白质多肽。所述干细胞培养基适用于源自人和哺乳动物组织的干细胞的快速培养，包括但不限于脂肪间充质干细胞，骨髓间充质干细胞和脐带血干细胞。所述培养基可以增加干细胞的增殖速度3-5次，对其分化潜能没有任何影响。将所述干细胞培养基与常规培养基进行比较，所述培养基不仅可以更快速地增殖源自不同来源的干细胞，而且可以实现更多的增殖代数，而且能够很好地保持其分化潜力。

63. 发明申请

US20140050665A1 METHOD FOR THE TREATMENT OR PROPHYLAXIS OF LYMPHANGIOLEIOMYOMATOSIS (LAM) AND ANIMAL MODEL FOR USE IN LAM RESEARCH 审中-公开
标题翻译：用于治疗或预防淋巴球蛋白病（LAM）的方法和用于研究的动物模型
公开(公告)号：US20140050665A1
公开(公告)日：2014-02-20
申请号：US13963291
申请日：2013-08-09
申请人： Fox Chase Cancer Center
发明人： Elizabeth Petri HENSKE , Jane YU
IPC分类号： A61K31/439 , A01K67/027 , A61K49/00
CPC分类号： A61K31/439 , A01K67/0271 , A61K31/16 , A61K45/06 , A61K49/0008 , C12N5/0693 , C12N2501/39 , G01N33/5088 , G01N33/57423 , A61K2300/00
摘要： Treatment of lymphangioleiomyomatosis with the MEK1/2 inhibitor CI-1040 delayed the development of primary tumors and blocked the estrogen-induced lung metastases in treated animals. Such treatment also reduced the number of circulating ELT3 cells and decreased their lung colonization after intravenous injection.
摘要翻译：用MEK1 / 2抑制剂CI-1040治疗淋巴管平滑肌瘤病可延缓原发性肿瘤的发展，阻断治疗动物中雌激素诱导的肺转移。这种治疗也减少了循环的ELT3细胞的数量，并且在静脉内注射后减少其肺定植。

64. 发明申请

US20130315884A1 METHODS FOR ENGINEERING ALLOGENEIC AND IMMUNOSUPPRESSIVE RESISTANT T CELL FOR IMMUNOTHERAPY 审中-公开
标题翻译：工程用免疫球蛋白免疫抑制剂T细胞的方法
公开(公告)号：US20130315884A1
公开(公告)日：2013-11-28
申请号：US13892805
申请日：2013-05-13
申请人： Roman Galetto , Agnès Gouble , Stéphanie Grosse , Cécile Mannioui , Laurent Poirot , Andrew Scharenberg , Julianne Smith
发明人： Roman Galetto , Agnès Gouble , Stéphanie Grosse , Cécile Mannioui , Laurent Poirot , Andrew Scharenberg , Julianne Smith
IPC分类号： A61K35/14
CPC分类号： A61K35/17 , A61K38/00 , C07K14/7051 , C07K14/70517 , C07K14/70521 , C07K14/70578 , C07K16/28 , C07K16/2803 , C07K2317/14 , C07K2317/24 , C07K2317/569 , C07K2317/622 , C07K2319/00 , C07K2319/03 , C07K2319/74 , C12N5/0636 , C12N2501/39 , C12N2501/51 , C12N2501/515 , C12N2501/599 , C12N2502/99 , C12N2510/00
摘要： Methods for developing engineered T-cells for immunotherapy that are both non-alloreactive and resistant to immunosuppressive drugs. The present invention relates to methods for modifying T-cells by inactivating both genes encoding target for an immunosuppressive agent and T-cell receptor, in particular genes encoding CD52 and TCR. This method involves the use of specific rare cutting endonucleases, in particular TALE-nucleases (TAL effector endonuclease) and polynucleotides encoding such polypeptides, to precisely target a selection of key genes in T-cells, which are available from donors or from culture of primary cells. The invention opens the way to standard and affordable adoptive immunotherapy strategies for treating cancer and viral infections.
摘要翻译：用于免疫治疗的工程化T细胞的开发方法既非同种异体反应，又适用于免疫抑制药物。本发明涉及通过灭活编码免疫抑制剂和T细胞受体靶基因的两个基因，特别是编码CD52和TCR的基因来修饰T细胞的方法。该方法包括使用特定的稀有切割内切核酸酶，特别是TALE-核酸酶（TAL效应子内切核酸酶）和编码这种多肽的多核苷酸，以精确地靶向T细胞中的关键基因的选择，其可从供体或从原代培养获得细胞。本发明开启了治疗癌症和病毒感染的标准和负担得起的过继免疫治疗策略的方法。

65. 发明授权

US08592209B2 Methods of preparing and characterizing mesenchymal stem cell aggregates and uses thereof 有权
标题翻译：制备和表征间充质干细胞聚集体的方法及其用途
公开(公告)号：US08592209B2
公开(公告)日：2013-11-26
申请号：US12162523
申请日：2007-01-30
申请人： Moshe Khurgel , Adam J. Katz
发明人： Moshe Khurgel , Adam J. Katz
IPC分类号： C12N5/02
CPC分类号： C12N5/0667 , A61K47/6901 , C12N2500/25 , C12N2500/36 , C12N2500/42 , C12N2501/10 , C12N2501/11 , C12N2501/135 , C12N2501/15 , C12N2501/23 , C12N2501/39 , C12N2501/392
摘要： The invention provides compositions and methods for preparing and characterizing multipotential mesenchymal stem cell aggregates. The invention further provides methods for using stem cell aggregates of the invention.
摘要翻译：本发明提供了用于制备和表征多潜能间充质干细胞聚集体的组合物和方法。本发明还提供了使用本发明的干细胞聚集体的方法。

66. 发明授权

US08592206B2 Culture based screening assay and methods of use thereof to identify agents which modulate tumor development, invasion and differentiation 有权
标题翻译：基于培养的筛选测定及其使用方法来鉴定调节肿瘤发生，侵袭和分化的药剂
公开(公告)号：US08592206B2
公开(公告)日：2013-11-26
申请号：US12771683
申请日：2010-04-30
申请人： Anil K. Rustgi , Carmen Z. Michaylira , Douglas B. Stairs
发明人： Anil K. Rustgi , Carmen Z. Michaylira , Douglas B. Stairs
IPC分类号： C12N5/00 , C12N5/07 , C12N5/10 , C12N15/00 , C12N15/09 , C12N15/113
CPC分类号： C12Q1/6876 , C12N5/0679 , C12N5/0697 , C12N2500/25 , C12N2500/32 , C12N2500/40 , C12N2501/39 , C12N2501/392 , C12N2501/395 , C12N2502/1323 , C12N2502/23 , C12N2502/30 , C12N2503/04 , C12N2533/54 , C12Q2600/112 , C12Q2600/158 , C12Q2600/16 , G01N33/5044 , G01N33/54306 , G01N2333/4706
摘要： A 3D organotypic culture which phenocopies aggressive, invasive cancer and methods of use thereof are provided.
摘要翻译：提供了具有侵略性侵袭性侵袭性癌症及其使用方法的3D器官型培养物。

67. 发明授权

US08507266B2 Apparatus and method for tissue engineering 有权
标题翻译：组织工程的装置和方法
公开(公告)号：US08507266B2
公开(公告)日：2013-08-13
申请号：US10578212
申请日：2004-11-04
申请人： Jean F. Welter , Luis A. Solchaga , Jim A. Berilla , Kitsie Penick
发明人： Jean F. Welter , Luis A. Solchaga , Jim A. Berilla , Kitsie Penick
IPC分类号： C12M1/22 , C12M3/00
CPC分类号： C12N5/0655 , C12M21/08 , C12M23/24 , C12M23/34 , C12M29/04 , C12M29/14 , C12M41/40 , C12N2501/115 , C12N2501/39
摘要： A bioreactor system includes a housing and a hydrostatic loading module. The housing includes a chamber with an inlet port and an outlet port. The inlet and outlet ports allowing the chamber to be continuously perfused with a culture medium while chamber is hydrostatically loaded.
摘要翻译：生物反应器系统包括壳体和静液压加载模块。壳体包括具有入口和出口的腔室。入口和出口允许腔室用培养基连续灌注，同时腔室被静液体加载。

68. 发明申请

US20130071931A1 PROCESS FOR HEPATIC DIFFERENTIATION FROM INDUCED HEPATIC STEM CELLS, AND INDUCED HEPATIC PROGENITOR CELLS DIFFERENTIATED THEREBY 审中-公开
标题翻译：诱导性肝细胞干细胞分化过程及其诱导的HEPICAL PROGENITOR CELLS差异化
公开(公告)号：US20130071931A1
公开(公告)日：2013-03-21
申请号：US13564803
申请日：2012-08-02
申请人： Tetsuya Ishikawa
发明人： Tetsuya Ishikawa
IPC分类号： C12N5/071
CPC分类号： C12N5/067 , C12N5/0671 , C12N2500/30 , C12N2500/36 , C12N2500/62 , C12N2501/115 , C12N2501/15 , C12N2501/237 , C12N2501/39 , C12N2501/727 , C12N2533/54 , C12N2533/90
摘要： A method for hepatic differentiation of a stem cell selected from among embryonic stem cells, induced pluripotent stem cells or induced hepatic stem cells is presented. More specifically, a stem cell selected from among embryonic stem cells, induced pluripotent stem cells or induced hepatic stem cells is cultured for 1 to 4 weeks in the presence of a TGF-β inhibitor, whereby the hepatic differentiation of the stem cell is realized.
摘要翻译：提出了选自胚胎干细胞，诱导多能干细胞或诱导的肝干细胞的干细胞的肝分化方法。更具体地说，在TGF-β1的存在下，将选自胚胎干细胞，诱导的多能干细胞或诱导的肝干细胞的干细胞培养1〜4周。抑制剂，从而实现干细胞的肝分化。

69. 发明申请

US20130064800A1 Tissue-Engineered Endothelial and Epithelial Implants Differentially and Synergistically Regulate Tissue Repair 审中-公开
标题翻译：组织工程内皮和上皮植入物差异性和协同调节组织修复
公开(公告)号：US20130064800A1
公开(公告)日：2013-03-14
申请号：US13571494
申请日：2012-08-10
申请人： Elazer R. Edelman , Brett G. Zani
发明人： Elazer R. Edelman , Brett G. Zani
IPC分类号： A61K35/12 , A61P17/02 , A61P1/00 , A61P15/00 , A61P11/00 , A61P9/00
CPC分类号： A61K35/36 , A61K35/12 , A61K35/42 , A61L27/3808 , C12N5/0688 , C12N2500/38 , C12N2501/11 , C12N2501/115 , C12N2501/25 , C12N2501/385 , C12N2501/39 , C12N2501/395 , C12N2501/81 , C12N2502/28 , C12N2533/00 , C12N2533/54
摘要： Endothelial implants restore vascular homeostasis after injury without reconstituting vascular architecture. Endothelial cells line the vascular epithelium and underlying vasa vasorum precluding distinction between cellular controls. Unlike blood vessels, the airway epithelium is highly differentiated and distinct from endothelial cells that line the bronchial vasa allowing investigation of the differential control tissue engineered cells may provide in airways and blood vessels. Through airway injury and cell culture models, tissue engineered implants of the bronchial epithelium and endothelium were found to promote synergistic repair of the airway through biochemical regulation of the airway microenvironment. While epithelial cells modulate local tissue composition and reaction, endothelial cells preserve the epithelium; together their relative impact was enhanced suggesting both cell types act synergistically for airway repair.
摘要翻译：内皮植入物在损伤后恢复血管稳态，而不会重建血管结构。内皮细胞对血管上皮细胞和下面的vasa血管排除细胞对照之间的区别。与血管不同，气道上皮与血管内皮细胞高度分化，区别于支气管血管，允许调查差异对照组织工程细胞可能在气道和血管中提供。通过气道损伤和细胞培养模型，发现支气管上皮和内皮的组织工程植入物通过气道微环境的生物化学调节促进气道的协同修复。虽然上皮细胞调节局部组织组成和反应，内皮细胞保留上皮细胞; 一起，他们的相对影响被增强，表明两种细胞类型协同作用用于气道修复。

70. 发明申请

US20130055417A1 HORMONE RESPONSIVE TISSUE CULTURE SYSTEM AND USES THEREOF 有权
标题翻译： HORMONE反应组织文化系统及其用途
公开(公告)号：US20130055417A1
公开(公告)日：2013-02-28
申请号：US13555968
申请日：2012-07-23
申请人： Tan A. Ince , Robert A. Weinberg
发明人： Tan A. Ince , Robert A. Weinberg
IPC分类号： C12N5/095 , C12Q1/02 , G01N33/574 , A61K49/00 , C12Q1/68 , C07H19/16 , C07K9/00 , C12N5/071 , C12N15/85
CPC分类号： C12N5/0631 , C12N15/85 , C12N2500/05 , C12N2500/24 , C12N2500/36 , C12N2500/42 , C12N2500/60 , C12N2501/01 , C12N2501/11 , C12N2501/33 , C12N2501/39 , C12N2501/392 , C12N2501/395
摘要： The invention provides tissue culture system for primary cells (e.g. normal mammalian primary epithelial progenitors). This system includes: a) a serum-free, chemically defined cell culture media; and, b) methods for isolation and in vitro long-term propagation of primary cells (e.g. primary epithelial cells). Primary cells so isolated and cultured can be kept undifferentiated and proliferate for many weeks (>15 weeks) or population doubling (>35 PD) without senescence, or any detectable genetic alterations. Upon changing media/culture conditions, these cells can be induced to differentiate.The invention also provides methods to transform normal primary cells so cultured into “cancer stem cells.” The genetically defined cancer stem cell tumor model mimics the behavior of the disease closely, e.g., the cells are invasive, hormone responsive and metastatic when injected into mice. The tumor cells express genes that are specific to cancer stem cells identified in patient samples.
摘要翻译：本发明提供了用于原代细胞的组织培养系统（例如，正常的哺乳动物原代上皮祖细胞）。该系统包括：a）无血清，化学定义的细胞培养基; 和b）原代细胞（例如原发性上皮细胞）的分离和体外长期繁殖的方法。如此分离和培养的原代细胞可以保持未分化和增殖多个星期（> 15周）或增殖倍数（> 35PD）而不衰老或任何可检测的遗传改变。改变培养基/培养条件后，可诱导这些细胞分化。本发明还提供了将如此培养成癌干细胞的正常原代细胞转化的方法。遗传定义的癌症干细胞肿瘤模型密切地模拟疾病的行为，例如，当注射入小鼠时，细胞是侵入性的，激素反应性的和转移的。肿瘤细胞表达在患者样品中鉴定的癌干细胞特异的基因。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式